Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Current Liabilities (2020 - 2026)

InMed Pharmaceuticals has reported Total Current Liabilities over the past 5 years, most recently at $1.5 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 17.36% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 17.36%, while the annual FY2025 figure was $1.8 million, 6.7% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $1.5 million at InMed Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $4.6 million in Q4 2021 and troughed at $1.3 million in Q3 2023.
  • A 5-year average of $2.2 million and a median of $1.9 million in 2021 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: surged 70.32% in 2022 and later tumbled 59.19% in 2023.
  • Year by year, Total Current Liabilities stood at $4.6 million in 2021, then plummeted by 48.01% to $2.4 million in 2022, then crashed by 30.0% to $1.7 million in 2023, then grew by 6.57% to $1.8 million in 2024, then decreased by 17.36% to $1.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for INM at $1.5 million in Q4 2025, $1.6 million in Q3 2025, and $1.8 million in Q2 2025.